ORIGINAL ARTICLE. Received March 9, 2009; accepted July 14, 2009.
|
|
- Randall Rolf Morton
- 5 years ago
- Views:
Transcription
1 LIVER TRANSPLANTATION 15: , 2009 ORIGINAL ARTICLE Comparison of Pharmacokinetics of Mycophenolic Acid and Its Metabolites Between Living Donor Liver Transplant Recipients and Deceased Donor Liver Transplant Recipients Shen Baiyong, 1 * Chen Bing, 2 * Zhang Weixia, 2 Mao Huarong, 1 Shen Chuan, 1 Deng Xiaxing, 1 Zhan Xi, 1 and Chen Hao 1 From the 1 Center of Organ Transplantation, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; and 2 Institute of Clinical Pharmacology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Living-donor liver transplantation (LDLT) has been considered an alternative method for treatment of patients with end-stage liver disease. However, the characteristics of pharmacokinetics of mycophenolic acid (MPA) in patients who underwent LDLT were not clear. This study was designed to compare the pharmacokinetics of MPA and its metabolites between LDLT patients and deceased donor liver transplant (DDLT) patients after oral administration of mycophenolate mofetil (MMF). Thirteen patients who underwent LDLT and 14 patients who underwent DDLT were enrolled prospectively. All patients received oral MMF administration (1.0 g, twice daily) in combination with tacrolimus (TAC). The plasma concentrations of MPA, free MPA, glucuronide (MPAG), and acyl glucuronide (AcMPAG) was determined by high-performance liquid chromatography method. There was a wide variation in various pharmacokinetic parameters of MPA and its metabolites in patients who underwent LDLT and DDLT after oral MMF administration. Although mean MPA area under the plasma concentration time curve for 0-12 hours (AUC 0-12h ) of MPA and MPAG in DDLT patients were higher than those in LDLT patients, there was no significant difference between the two groups. MPA concentration at 6 hours (C 6h ), C 10h,C 12h, and MPA AUC 6-12h were significantly higher in DDLT group than those in LDLT group (P 0.05). Inversely, higher free MPA AUC 0-12h and significant free MPA fraction (P 0.05) in LDLT patients were observed in DDLT patients when compared with DDLT group. AcMPAG concentrations at 4, 8, and 10 hours and AcMPAG AUC 0-12h were significantly higher in the DDLT group (P 0.05). In conclusion, after a fixed oral dose of MMF, DDLT patients had higher enterohepatic recycling contributing to total MPA exposure compared with LDLT patients. The function of glucuronide conjugation in LDLT patients was decreased compared with that in DDLT patients. Higher free MPA AUC 0-12h and a significantly higher fraction of free MPA in LDLT patients suggested that a lower oral dose of MMF may be administered for patients who underwent LDLT. Liver Transpl 15: , AASLD. Received March 9, 2009; accepted July 14, Mycophenolate mofetil (MMF) has been widely used for the prevention of acute rejection in liver transplantation. 1 It was suggested that MMF allows the safe reduction of calcineurin inibitor dose with a low risk of rejection and an improvement in renal function. 2 After oral administration, MMF is rapidly hydrolysed to the active Abbreviations: AcMPAG, acyl glucuronide; AUC, area under the plasma concentration time curve; CL/F, oral clearance; C 0h and C max, predose and maximum (peak) concentrations; MMF, mycophenolate mofetil; MPA, mycophenolic acid; MPAG, glucuronide. *These authors contributed equally to this study. This study was supported by Natural Science Foundation of Shanghai (No: 08ZR ). The authors have no conflicts of interest that are directly relevant to the content of this study. Address reprint requests to Chen Hao, Center of Organ Transplantation, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Shanghai , China. Telephone: 86(0) ; haochendr@yahoo.com.cn; fax: DOI /lt Published online in Wiley InterScience ( American Association for the Study of Liver Diseases.
2 1474 BAIYONG ET AL. product, mycophenolic acid (MPA). 3 Subsequently MPA is extensively metabolized by uridine diphosphate glucuronsyltransferase enzymes in the liver, gut, and kidney to its inactive metabolite, phenyl mycophenolic acid glucuronide (MPAG). 4 MPAG is extensively bound to serum albumin, from which it can displace MPA, and is excreted in the urine and bile 5. A second and less abundant metabolite is the acyl glucuronide (AcMPAG). Unlike MPAG, AcMPAG is pharmacologically active. AcM- PAG plasma concentrations in patients treated with MMF reach an average of 10%-20% at respective MPA concentrations. 6,7 MPA is an acidic compound that is extensively ( 95%) bound to albumin at clinically relevant concentrations. However, free MPA (fmpa), rather than total MPA, is the pharmacologically active form of the drug. 8 It has been confirmed by some investigations that interpatient variability of MPA exposure in LT recipients and also there are few data to provide guidelines for therapeutic drug monitoring after liver transplantation. 9,10 In our previous study, a large interindividual variability of MPA area under the curve (AUC) has been observed in decreased donor liver transplant (DDLT) patients who received a fixed dose of 1 g MMF twice daily. 11 Many patients have decreased total MPA exposure due to low concentrations of albumin and high concentrations of bilirubin. 12 An increased free fraction (decrease in protein binding) can lead to lower total MPA concentrations and relatively unchanged fmpa concentrations by a restrictive clearance mechanism. The study by van Gelder et al. 13 suggested that any investigation of the pharmacokinetics of MMF in liver transplant patients should measure both free and total concentrations. Recently, living donor liver transplantation (LDLT) has been performed worldwide for treatment of patients with end-stage liver disease and for overcoming the serious shortage of deceased donors. Because the LDLT patients receive only about half of normal hepatic volume, the small hepatic volume could affect the pharmacokinetics of immunosuppressive agents In the current study, we evaluated the pharmacokinetics of MPA and its metabolites after oral MMF administration in LDLT patients and in DDLT patients as well. PATIENTS AND METHODS Patients The study design was approved by the independent ethics committee of Ruijin Hospital, and the procedure was described in detail to all patients before admission and informed consent was obtained. Thirteen LDLT patients and fourteen DDLT patients were enrolled prospectively in this study in the Organ Transplantation Center of Ruijin Hospital. Immunosuppressive Protocol Triple immunosuppressive protocol including MMF (Cellcept, Roche), tacrolimus (TAC; Prograf, Astellas), and steroid was used in two groups of patients. One gram of MMF was given within 6 hours before liver transplantation and 1.0 g was administered twice daily after transplant operation. TAC was given 2 hours later than MMF. Trough concentration of TAC was monitored daily. The dose of TAC was adjusted according to the target range of 5-10 ng/ml. Methylprednisolone was injected during the anhepatic period, and dosage was tapered after operation. After 1 week, prednisone was given at 20 mg daily. Basiliximab (Simulect, Novartis) was taken for immune induction therapy. Blood Sampling A set of blood samples was taken respectively in two groups of patients within the second week after transplantation. Blood samples for analysis of MMF concentration were obtained before dose and at 0.5, 1, 1.5, 2, 4, 6, 8, 10, and 12 hours after dosing. All plasma samples were stored at 20 C until analysis. In addition, laboratory tests were also taken at MPA sampling day. MPA Pharmacokinetic Analysis Concentration of MPA, fmpa, MPAG, and AcMPGA were determined using a high-performance liquid chromatography (HPLC) procedure. The accuracy of the HPLC method used in the Institute of Clinical Pharmacology of Ruijin Hospital was ensured by participating in the MPA Proficiency Testing Scheme, provided by the Cardiac and Vascular Sciences Analytic Unit, St. George s Hospital Medical School (London, UK). The HPLC system includes an isocratic pump, a diode array detector, and an automatic sampling system (all components are from Angilent system, Germany). A Zorbax Eclipse XDB C18 column (250 mm 4.6 mm internal diameter, and 5 m pore size) was used to carry out the separation. The mobile phase consisted of 20 mmol/l NaH 2 PO 4 buffer (ph 3.0, adjusted with 20% phosphoric acid) and methanol (45:55, vol/vol), the column temperature was 45 C, and the flow rate was 1.2 ml/minute. The detector wavelength was set at 304 nm. Ethylene diamine tetraacetic acid plasma (100 L) was mixed with 5 L 20% phosphoric acid in an Eppendorf tube. Protein-precipitating reagent (100 L) was added. The tubes were mixed for 20 seconds on a vortex machine and then centrifuged at 13,000 rpm for 10 minutes. Then, 20 L of the clear supernatant was injected into a Waters HPLC system. The MPA, MPAG, and AcMPAG concentrations were calculated with the ratio of the peak areas of these analyses and IS. Another 0.5 ml of supernatant was added to the Vivaspin 500 ultrafiltration devices (Satorius Stedim Biotech), and a molecular weight cutoff of 10 kda was used to generate plasma ultrafiltrate. The devices were centrifuged in an Eppendorf 5804R centrifuge with fixed-angle rotor (Eppendorf Inc., Hamburg, Germany) at 10,000 rpm for 30 minutes at 25 C. Twenty L of ultrafiltrate was injected into a Waters HPLC system with a 2475 fluorescence detector. The fmpa was separated on a Zorbax Eclipse XDB C18 column (250 mm 4.6 mm internal diameter, 5 m pore size) with the mobile phase consist-
3 MYCOPHENOLIC ACID PHARMACOKINETICS IN LIVER TRANSPLANT RECIPIENTS 1475 TABLE 1. Demographics of LDLT Patients and DDLT Patients Characteristic LDLT DDLT Sex (M/F) 11/2 13/1 Age Body weight (kg) Body height (cm) Primary hepatic diseases Hepatitis B viral cirrhosis with hepatocellulor carcinomas 5 3 Hepatitis B viral cirrhosis 3 7 Severe hepatitis B 2 2 Secondary biliary cirrhosis 0 1 Wilson s disease 3 0 Intrahepatic cholestasis after liver transplantation 0 1 TABLE 2. Comparison of Laboratory Tests Between LDLT Group and DDLT Group Parameter LDLT DDLT P Values Red blood count ( 10 9 /L) Hemoglobin (g/l) Hematocrit (%) White blood count ( 10 9 /L) Platelet ( 10 9 /L) Aspartate aminotransferase (U/L) Alanine aminotransferase (U/L) Gamma glutamyl transpeptidase (U/L) Alkaline phosphatase (U/L) Serum albumin (g/l) Serum total bilirubin (mmol/l) Serum creatine (mmol/l) ing of buffer (10 mmol/l Na 2 HPO 4 and 15 mmol/l of Tris boric acid, ph 8.5) and methanol (40:60, vol/vol), with flow rate set at 1.0 ml/minute. The wavelengths of detection were set at 342 nm (excitation) and 425 nm (emission), respectively. Winnolin 4.1 software was adopted to calculate t max, maximum concentration (C max ), AUC 0-12h of MPA, fmpa, MPAG, AcMPAG, area under the moment curve (AUMC), oral clearance (CL/F), and mean residence time (MRT) of MPA by using noncompartmental analysis. Full 12-hour AUC was determined according to the linear trapezoidal rule. Fraction of fmpa was calculated by dividing fmpa concentrations by total MPA concentrations. The parentto-metabolite concentration ratios were calculated by dividing MPA concentrations by MPAG and AcMPAG concentrations. The differences in the MPA and glucuronide molecular weights were used to correct the ratios. Because the molecular weight of MPAG and AcMPAG are identical, no correction was applied to calculate MPAG to AcMPAG concentration ratio. Statistical Analysis SPSS 13.0 software for Windows was used for statistical analysis. Data were expressed as the mean standard deviations and a P value below 0.05 was considered to be statistically significant. Grouped data were compared by the Mann-Whitney U test. RESULTS The demographics of these two groups of patients, including age, body weight, body height, and primary liver disease, are shown in Table 1. On the sampling day, the laboratory test results were compared between the two groups. There was no significant difference in the majority of laboratory parameters including serum albumin, total bilirubin, and creatine levels except for white blood counts (Table 2). Figures 1-4 represent concentration time profiles of MPA and related compounds. There was a wide variation in various pharmacokinetic parameters of MPA and its metabolites after oral MMF administration in patients who had undergone LDLT and DDLT. Total MPA concentrations were significantly higher at 6, 10, and 12 hours after dose in the DDLT group (Fig. 1). The pharmacokinetic properties of MPA and fmpa are shown in Table 3. Higher CL/F (P 0.073) and significantly lower MPA AUMC (P 0.05) were evident in the LDLT group as compared to the DDLT group. Although, on average, patients who had undergone DDLT had higher MPA AUC 0-12h than patients who had undergone LDLT, MPA AUC 0-12h values were not significantly different between the two groups (P 0.099). However, MPA AUC 6-12h, which is the indicator of enterohepatic recirculation of MPA, was significantly lower in the LDLT group than that in the DDLT group (P 0.05).
4 1476 BAIYONG ET AL. Figure 1. Comparison of the mean plasma concentration time profile of MPA between the LDLT group and the DDLT group. *P < Figure 2. Comparison of mean plasma concentration time profile of free MPA between the LDLT group and the DDLT group. Inversely, on average, patients in the DDLT group had lower free MPA AUC 0-12h than patients in the LDLT group, and the values were not significantly different as well (P 0.159). There was no significantly difference in T max,c max of MPA and fmpa between the two groups (Table 3). And the concentrations of free MPA during the 12-hour interval were not significantly different between the two groups (Fig. 2). However, the percentage of free MPA, which is the indicator of extent of plasma protein binding, was significantly higher in LDLT patients than that in DDLT patients (P 0.05). DISCUSSION This is the first study to compare the pharmacokinetics of MPA and its metabolites after oral MMF administration between patients who had undergone LDLT and DDLT. Furthermore, we are the first to have measured fmpa concentrations in LDLT and DDLT pa-
5 MYCOPHENOLIC ACID PHARMACOKINETICS IN LIVER TRANSPLANT RECIPIENTS 1477 Figure 3. Comparison of mean plasma concentration time profile of MPAG between the LDLT group and the DDLT group. Figure 4. Comparison of mean plasma concentration time profile of AcMPAG between the the LDLT group and the DDLT group. * P < 0.05 tients. Some observations are interesting and noteworthy. Large interindividual variation in MPA pharmacokinetics after oral administration has been well-recognized in liver transplant recipients. 9,11,17 In this study, such a phenomenon still remained not only in DDLT patients but also in LDLT patients. By applying an identical oral dosage regimen, the plasma MPA AUC 0-12h was higher in DDLT patients compared with LDLT patients, although a significant difference was not reached. In addition, MPA C 6h,C 10h,C 12h, and MPA AUC 6-12h were significantly higher in the DDLT group than those in the LDLT group (P 0.05). These results showed that more MPAG was excreted into the
6 1478 BAIYONG ET AL. TABLE 3. Comparison of MPA and Free MPA Pharmacokinetics Between the LDLT Group and the DDLT Group LDLT DDLT P Value MPA T max (hours) C 0h (mg/l) C max (mg/l) AUMC (mg.hour 2 /L) MRT (hours) CL/F (L/hour) AUC 6-12h (mg.hour/l) AUC 0-12h (mg.hour/l) free MPA T max (hour) C 0h ( g/l) C max ( g/l) AUC 0-12h ( g.hour/l) Fraction free (%) Abbreviations: AUMC, area under moment curve; MRT, mean residence time; MPA, mycophenolic acid; AUC, area under curve. TABLE 4. Comparison of MPA Metabolites Pharmacokinetics Between the LDLT Group and the DDLT Group LDLT DDLT P Value MPAG T max (hours) C 0h (mg/l) C max (mg/l) AUC 0-12h (mg.hour/l) AcMPAG T max (hours) C 0h (mg/l) C max (mg/l) AUC 0-12h (mg.hour/l) MPAG to AcMPAG concentration ratio MPA to MPAG concentration ratio MPA to AcMPAG concentration ratio Abbreviations: MPAG, mycophenolic acid glucoronide, AcMPAG, acyl mycophenolic acid glucoranide; MPA, mycophenolic acid; AUC, area under curve. bile and was deconjugated back to MPA leading to more MPA reabsorbed in the colon in the DDLT group. Shaw et al. 18 suggested that the occurrence of a secondary MPA concentration peak anywhere from 4-12 hours following the morning dose of MMF is thought to be the result of enterohepatic recycling. It was evident that enterohepatic recycling contributes more to MPA exposure in the DDLT group compared with the LDLT group. However, CL/F of MPA was higher in the LDLT group than that in the DDLT group. These results were opposite to the observations by Jain et al., 16 in which, after intravenous MMF administration, MPA AUC 0-12h was significantly higher and CL/F was significantly lower in the LDLT patients compared with the DDLT patients. Two reasons could explain such differences. First, the pathway of drug administration was different. Second, blood samples were obtained on postoperative day 2 or day 3 in the study by Jain et al. In our study, blood samples were drawn on the second postoperative week. In an experiment in partially hepatectomized rats, Tian et al. 19 reported that the hepatic intrinsic clearance of MPA was decreased to 52% and 51% of that in control rats at the 24th hour and the 6th day, respectively, but recovered to normal level by day 14. The total body clearance of MPA was reduced at the 24th hour but recovered by day 6. We thought that the total body clearance of MPA was recovered after the second week both in LDLT and DDLT patients. Some factors including body weight, serum albumin concentration, renal function, and immunosuppressant cotherapy have a significant influence on CL/F. 5 In population pharmacokinetic studies in renal transplant recipients, MPA CL/F in adults ranges from 11.9 to 25.4 L/hour under the combination of tacrolimus therapy. 20 In the current study, these factors
7 MYCOPHENOLIC ACID PHARMACOKINETICS IN LIVER TRANSPLANT RECIPIENTS 1479 were similar in DDLT and LDLT patients. Therefore, the reason for higher CL/F in the LDLT group was not clear and perhaps was related to the hepatic regeneration. Another important observation in this study was that the fmpa fraction was significantly higher in the LDLT group than that in the DDLT group (P 0.05). The fmpa AUC 0-12h was also higher in patients with LDLT, although they were not significantly different. Total MPA CL/F appears to increase in proportion to the increased free fraction, with a reduction in total MPA AUC. 21 Because the total MPA concentration appears to be reduced due to increased CL/F, the net result may vary little in the absolute free concentration of MPA. MPA is extensively bound to albumin at clinically relevant concentrations. The degree of protein binding has a significant intraindividual and interindividual variation due to factors such as serum albumin concentration, renal function, and coadministration of drugs which may compete with and/or displace MPA from its protein binding sites. 8,22 Free MPA concentration seems to be constant in patients with preserved renal function. In stable transplant patients, the fmpa fraction ranges from 1%-3%. 22 The factors leading to increased fmpa concentration included patients with poor renal function, liver disease, hypoalbuminemia, and severe infection. 23,24 Shaw et al. 25 suggested that an increase of two-fold to three-fold in fmpa concentration was shown in patients with renal failure. Because the conditions before and after operation were not different in LDLT group and DDLT group in the current study, the reason for increased free MPA AUC and fraction fmpa was directly related to increased CL/F. Nowak et al. 8 has shown that fmpa, rather than total MPA, is the pharmacologically active form of the drug. As such, it has been suggested that measurement of fmpa is more relevant to therapeutic outcomes when compared to total MPA concentration in liver transplantation. 8,13 In patients with impaired renal or hepatic function or hypoalbuminaemia, free drug measurement could be valuable in further interpretation of MPA exposure. After oral administration of MMF, glucuronidation of MPA to MPAG and AcMPAG in LDLT patients was somewhat inefficient compared with that in DDLT patients. The MPAG concentrations were higher in DDLT patients than those in LDLT recipients at all the sampling time points. These results were consistent with the observations in the study by intravenous infusion of MMF. 16 Tian et al. 26 reported that the function of glucuronide conjugation was impaired after partial hepatectomy in rats and was recovered completely within 2 weeks with hepatic regeneration. The activity of glucuronide-conjugating enzymes was decreased due to reduced liver mass during the hepatic regeneration process. These observations suggested that the ability of clearance of MPA has decreased in LDLT patients during the early period after operation. Higher MPAG concentrations have been reported in patients with renal dysfunction 6 and MPAG clearance is also dependent on renal function in liver transplant recipients. 27 Because renal function in DDLT patients decreased compared with LDLT patients (lower serum creatine level), the higher MPAG concentrations may be due to the impaired elimination of MPAG in DDLT patients. In addition, a higher serum level of total bilirubin was observed in DDLT patients. Hyperbilirubinemia may be a factor influencing the pharmacokinetics of MPA. However, higher bilirubin concentrations seemed not to lead to the reduction of hepatic glucuronidation. The results from the study by Parker et al. 28 suggested that hepatic cirrhosis did not significantly affect plasma protein binding of MPA or MPAG, and reduced hepatic glucuronidation of MPA may be compensated by enhanced renal glucuronidation. In another study by Jain et al. 2, it was suggested that T-tube clamping did not affect the pharmacokinetics of MPA or MPAG over one dosing interval. We thought that the impact of hyperbilirubinemia on hepatic glucuronidation of MPA has not been understood definitely. In conclusion, after a fixed oral dose of MMF, lower MPA AUC 0-12h and significant lower MPA AUC 6-12h were observed in LDLT patients. DDLT patients had higher enterohepatic recycling contribution to total MPA exposure. Inversely, higher free MPA AUC and significant higher fraction free MPA were observed in LDLT patients. As free MPA is the pharmacologically active form, lower oral dose of MMF may be administered for LDLT patients. On the other hand, the function of glucuronide conjugation in LDLT patients was decreased with lower AUC of MPA and MPAG compared with DDLT patients. These results will provide the primary data for understanding the difference of pharmacokinetics of MPA and its compounds between LDLT patients and DDLT patients. ACKNOWLEDGMENT The authors thank Dr. Lu Hui for revision of this article and for the hard work of all nurses at the Center of Organ Transplantation. REFERENCES 1. Manzia TM, De Liguori Carino N, Orlando G, Toti L, De Luca L, D Andria D, et al. Use of mycophenolate mofetil in liver transplantation: a literature review. Transplant Proc 2005;37: Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 20014;357: Bullingham RES, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 1996;28: Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34: Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007;46: Kuypers DR, Vanrenterghem Y, Squifflet JP, Mourad M, Abramowicz D, Oellerich M, et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination
8 1480 BAIYONG ET AL. with mycophenolate mofetil. Ther Drug Monit 2003;25: Shipkova M, Armstrong VW, Weber L, Niedmann PD, Wieland E, Haley J, et al. Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 2002;24: Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995;41: Tredger JM, Brown NW, Adams J, Gonde CE, Dbawan A, Rela M, et al. Monitoring Mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl 2004;10: Hao C, Anwei M, Bing C, Baiyong S, Weixia Z, Chuan S, et al. Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia. Liver Transpl 2008;14: Chen H, Peng C, Yu Z, Shen B, Deng X, Qiu W, et al. Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. Clin Pharmacokinet 2007;46: Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001; 23: van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28: Charco R, Rimola A, Garcia-Valdecasas JC, Fuster J, Fondevila C, Navasa M, et al. Steroids and living liver donation increase tacrolimus blood levels in living donor liver transplantation. Transplant Proc. 2005;37: Jain A, Venkataramanan R, Sharma R, Kwong T, Orloff M, Abt P, et al. Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. Transplantation 2008;85: Jain A, Venkataramanan R, Sharma R, Kwong T, Abt P, Orloff M, et al. Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients. J Clin Pharmacol 2008;48: Jain A, Venkataramanan R, Kwong T, Mohanka R, Orloff M, Abt P, et al. Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. Liver Transpl 2007 ;136: Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003;3: Tian H, Ou J, Strom SC, Venkataramanan R. Pharmacokinetics of tacrolimus and mycophenolic acid are altered, but recover at different times during hepatic regeneration in rats. Drug Metab Dispos 2005;33: Cremers S, Schoemaker R, Scholten E, den Hartigh J, König-Quartel J, van Kan E, et al. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. Br J Clin Pharmacol 2005;60: Weber LT, Shipkova M, Lamersdorf T, Niedmann PD, Wiesel M, Mandelbaum A, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1998; 9: Shaw LM, Korecka M, Aradhye S, Grossman R, Bayer L, Innes C, et al. Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol 2000;40: Kaplan B, Meier-Kriesche HU, Friedman G, Mulgaonkar S, Gruber S, Korecka M, et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Phamracol 1999;39: Meier-Kriesche HU, Shaw LM, Korecka M, Kaplan B. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther Drug Monit 2000;22: Shaw LM, Mick R, Nowak I, Korecka M, Brayman KL. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol 1998;38: Tian H, Ou J, Strom SC, Venkataramanan R. Activity and expression of various isoforms of uridine diphosphate glucuronosyltransferase are differentially regulated during hepatic regeneration in rats. Pharm Res 2005;22: Jain A, Venkataramanan R, Hamad IS, Zuckerman S, Zhang S, Lever J, et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol 2001;41: Parker G, Bullingham R, Kamm B, Hale M. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 1996;36: Jain AB, Hamad I, Zuckerman S, Zhang S, Warty VS, Fung JJ, et al. Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. Liver Transpl Surg 1999;5:
Validation of Limited Sampling Strategy for the Estimation of Mycophenolic Acid Exposure in Chinese Adult Liver Transplant Recipients
LIVER TRANSPLANTATION 13:1684-1693, 2007 ORIGINAL ARTICLE Validation of Limited Sampling Strategy for the Estimation of Mycophenolic Acid Exposure in Chinese Adult Liver Transplant Recipients Chen Hao,
More informationOptimization of the Dosing Regimen of Mycophenolate Mofetil in Pediatric Liver Transplant Recipients
LIVER TRANSPLANTATION 17:1152 1158, 2011 ORIGINAL ARTICLE Optimization of the Dosing Regimen of Mycophenolate Mofetil in Pediatric Liver Transplant Recipients Caroline Barau, 1 Aurélie Barrail-Tran, 1
More informationMycophenolate mofetil (MMF) is a purine analogue. Mycophenolic Acid Pharmacokinetics in Pediatric Liver Transplant Recipients
Mycophenolic Acid Pharmacokinetics in Pediatric Liver Transplant Recipients Marion M. Aw, Nigel W. Brown, Toshi Itsuka, Christopher E. Gonde, Jemimah E. Adams, Nigel D. Heaton, J. Michael Tredger, Giorgina
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationMycophenolate Blood Level Monitoring: Recent Progress
American Journal of Transplantation 2009; 9: 1495 1499 Wiley Periodicals Inc. Minireview C 2009 The Author Journal compilation C 2009 The American Society of Transplantation and the American Society of
More informationTomoyuki Enokiya 1, Kouhei Nishikawa 2, Yuichi Muraki 1, Takuya Iwamoto 1, Hideki Kanda 2, Yoshiki Sugimura 2 and Masahiro Okuda 1*
Enokiya et al. Journal of Pharmaceutical Health Care and Sciences (2017) 3:17 DOI 10.1186/s40780-017-0086-7 RESEARCH ARTICLE Open Access Usefulness of limited sampling strategy for mycophenolic acid area
More informationMycophenolic acid (MPA) is the active immunosuppressant
Monitoring Mycophenolate in Liver Transplant Recipients: Toward a Therapeutic Range John Michael Tredger, 1 Nigel William Brown, 1 Jemimah Adams, 1 Chris Elton Gonde, 1 Anil Dhawan, 2 Mohamed Rela, 3 and
More informationJ Am Soc Nephrol 13: , 2002
J Am Soc Nephrol 13: 759 768, 2002 The Pharmacokinetic-Pharmacodynamic Relationship for Total and Free Mycophenolic Acid in Pediatric Renal Transplant Recipients: A Report of the German Study Group on
More informationOriginal Article. This PDF is available for free download from a site hosted by Medknow Publications. (
Original Article www.jpgmonline.com A six-hour extrapolated sampling strategy for monitoring mycophenolic acid in renal transplant patients in the Indian subcontinent Fleming DH, Mathew BS, John GT*, Chandy
More informationMycophenolate mofetil (MMF) has become the single
Diagnostic & Therapeutic Corner Therapeutic Monitoring of Mycophenolate Mofetil Hyunyoung Jeong* and Bruce Kaplan *Department of Pharmacy Practice and Department of Medicine, University of Illinois at
More informationNIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 September 22.
NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1990 February ; 22(1): 57 59. Effect of Hepatic Dysfunction and T Tube Clamping on FK 506 Pharmacokinetics and Trough
More informationMycophenolate mofetil (MMF) is an immunosuppressive
Explaining Variability in Mycophenolic Acid Exposure to Optimize Mycophenolate Mofetil Dosing: A Population Pharmacokinetic Meta-Analysis of Mycophenolic Acid in Renal Transplant Recipients Reinier M.
More informationVariability in the pharmacokinetics of mycophenolic acid
Variability in the pharmacokinetics of mycophenolic acid Implications for therapeutic drug monitoring Brenda de Winter The publication of this thesis was financially supported by the Dutch Transplantation
More informationWhy and How to Perform Therapeutic Drug Monitoring for Mycophenolate Mofetil
Trends in Transplantation 2007;1:24-34 Why and How to Perform Therapeutic Drug Monitoring for Mycophenolate Mofetil Brenda de Winter and Teun van Gelder Department of Hospital Pharmacy, Clinical Pharmacology
More informationORIGINAL ARTICLE. GH Cochin-Saint Vincent-de-Paul, Paris, France; and 3 EA 3738, Université Lyon 1, Université de Lyon, Lyon, France
LIVER TRANSPLANTATION 14:1745-1751, 2008 ORIGINAL ARTICLE Comparison of a New Enzymatic Assay with a High-Performance Liquid Chromatography/ Ultraviolet Detection Method for Therapeutic Drug Monitoring
More informationLaboratory Monitoring of Cyclosporine Pre-dose Concentration (C 0 ) After Kidney Transplantation in Isfahan
IJMS Vol 28, No.2, June 2003 Original Article Laboratory Monitoring of Cyclosporine Pre-dose Concentration (C 0 ) After Kidney Transplantation in Isfahan Z. Tolou-Ghamari*, A.A. Palizban. Abstract Background:
More informationTDM. Measurement techniques used to determine cyclosporine level include:
TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.
More informationMycophenolic acid (MPA)-based therapies are widely
balt5/cjn-cjasn/cjn-cjasn/cjn00507/cjn2381-07a CJASN epress. Published hurtr on August S 13 8/15/07 16, 2007 13:24as 4/Color doi: 10.2215/CJN.03861106 Figure(s): 1&2 Art: 03861106 Input-ch Diagnostic and
More informationGeneral Introduction. 1 general introduction 13
General Introduction In The Netherlands 13,000 patients suffer from end stage renal disease (ESRD), which left untreated inevitably results in death. Every year this number increases with approximately
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationShin Hwang, Gi-Won Song, Dong-Hwan Jung, Gil-Chun Park, Chul-Soo Ahn, Deok-Bog Moon, Tae-Yong Ha, Ki-Hun Kim, and Sung-Gyu Lee
Ann Hepatobiliary Pancreat Surg 2017;21:11-16 https://doi.org/10.14701/ahbps.2017.21.1.11 Original Article Intra-individual variability of mycophenolic acid concentration according to renal function in
More informationProton Pump Inhibitors do not Interact with the Immunosuppressant Enteric-Coated Mycophenolate Sodium
Proton Pump Inhibitors do not Interact with the Immunosuppressant Enteric-Coated Mycophenolate Sodium S. Kofler, C. Wolf, Z. Sisic, J. Behr, M. Vogeser, M. Shipkova, B. Meiser, G. Steinbeck, B. Reichart,
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationEffect of Ganciclovir on Pharmacokinetics of Mycophenolic Mofetil, in Kidney Transplant Patients
Iranian Journal of Basic Medical Sciences Vol. 10, No. 4, Winter 2008, 233-238 Received: December 5, 2007; Accepted: March 2, 2008 Effect of Ganciclovir on Pharmacokinetics of Mycophenolic Mofetil, in
More informationPHA5128 Dose Optimization II Case Study I Spring 2013
Silsamicin is an investigational compound being evaluated for its antimicrobial effect. The route of administration for this drug is via intravenous bolus. Approximately 99.9% of this drug is eliminated
More informationDoes the formulation of tacrolimus matter?
Does the formulation of tacrolimus matter? This promotional meeting has been fully funded and organised by Astellas Pharma Ltd and Astellas products will be discussed. PI can be found at the end of this
More informationPharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents
BUMC Proceedings 1999;12:110-112 Pharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents CHERYLE GURK-TURNER, RPH Department of Pharmacy Services, BUMC wo mouse/human
More informationPharmacokinetic study of mycophenolic acid in Iranian kidney transplant patients.
2013 jpc.tums.ac.ir Pharmacokinetic study of mycophenolic acid in Iranian kidney transplant patients. Kheirollah Gholami 1, Mohammadreza Rouini 2, Niayesh Mohebbi 3, Iman Karimzadeh 3, Mehdi Ahadi barzoki
More informationBritish Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology DOI:1.1111/j.1365-2125.29.3612.x Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome
More informationMycophénolate mofétil
Mycophénolate mofétil O OH CH 3 O O-desmethyl O glucosides OH CH 3 OCH 3 CH 3 CYP 3A UGT2B7 C O HO O HO AcMPAG (acyl-glucuronide) ACTIF TOXIQUE O O CH 3 OCH 3 Mycophenolate (MPA) OH COOH UGT enzymes COOH
More informationSummary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Multicenter, Three Arm, Randomized, Open Label Clinical Study to Compare Renal Function in Liver Transplant Recipients Receiving an Immunosuppressive
More informationBK Virus (BKV) Management Guideline: July 2017
BK Virus (BKV) Management Guideline: July 2017 BK virus has up to a 60-80% seroprevalence rate in adults due to a primary oral or respiratory exposure in childhood. In the immumocompromised renal transplant
More informationNIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2011 April 6.
NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1991 December ; 23(6): 2777 2779. Pharmacokinetics of Cyclosporine and Nephrotoxicity in Orthotopic Liver Transplant
More informationCase Report Tacrolimus Toxicity due to Biliary Obstruction in a Combined Kidney and Liver Transplant Recipient
Hindawi Case Reports in Transplantation Volume 217, Article ID 996435, 4 pages https://doi.org/1.1155/217/996435 Case Report Tacrolimus Toxicity due to Biliary Obstruction in a Combined Kidney and Liver
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationMycophenolate mofetil (MMF) is an effective anti proliferative
OVERVIEW Controlled-Dose Versus Fixed-Dose Mycophenolate Mofetil for Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Xianding Wang, 1 Xin Qin, 1 Yong
More informationSummary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Multi-center, Randomized, Open-label, Pilot and Exploratory Study Investigating Safety and Efficacy in OPTIMIZEd Dosing of Advagraf Kidney
More informationNonlinear Relationship between Mycophenolate Mofetil Dose and Mycophenolic Acid Exposure: Implications for Therapeutic Drug Monitoring
Article Nonlinear Relationship between Mycophenolate Mofetil Dose and Mycophenolic Acid Exposure: Implications for Therapeutic Drug Monitoring Brenda C.M. de Winter,* Ron A.A. Mathot,* Ferdi Sombogaard,*
More informationLiving Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors?
Original Article Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? R. F. Saidi 1 *, Y. Li 2, S. A. Shah 2, N. Jabbour 2 1 Division of Organ Transplantation, Department
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationChapter 6: Transplantation
Chapter 6: Transplantation Introduction During calendar year 2012, 17,305 kidney transplants, including kidney-alone and kidney plus at least one additional organ, were performed in the United States.
More informationREACH Risk Evaluation to Achieve Cardiovascular Health
Dyslipidemia and transplantation History: An 8-year-old boy presented with generalized edema and hypertension. A renal biopsy confirmed a diagnosis of focal segmental glomerulosclerosis (FSGS). After his
More informationBioequivalence study of two different formulations of 300 mg gabapentin capsule in Thai healthy volunteers
70 Thai J. Pharm. Sci. 32 (2008) 70-76 Original article Bioequivalence study of two different formulations of 300 mg gabapentin capsule in Thai healthy volunteers Supeecha Wittayalertpanya*, Sumana Chompootaweep,
More informationComparison of PETINIA and LC-MS/MS for determining plasma mycophenolic acid concentrations in Japanese lung transplant recipients
Kikuchi et al. Journal of Pharmaceutical Health Care and Sciences (2018) 4:7 https://doi.org/10.1186/s40780-018-0101-7 SHORT REPORT Open Access Comparison of PETINIA and LC-MS/MS for determining plasma
More informationTacrolimus is a macrolide that was introduced into clinical
Pharmacokinetics of Tacrolimus in Living Donor Liver Transplant and Deceased Donor Liver Transplant Recipients Ashok Jain, 1,4 Raman Venkataramanan, 2 Rajeev Sharma, 1 Tai Kwong, 3 Mark Orloff, 1 Peter
More informationInduction Immunosuppression With Rabbit Antithymocyte Globulin in Pediatric Liver Transplantation
LIVER TRANSPLANTATION 12:1210-1214, 2006 ORIGINAL ARTICLE Induction Immunosuppression With Rabbit Antithymocyte Globulin in Pediatric Liver Transplantation Ashesh Shah, 1 Avinash Agarwal, 1 Richard Mangus,
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationDonor Hypernatremia Influences Outcomes Following Pediatric Liver Transplantation
8 Original Article Donor Hypernatremia Influences Outcomes Following Pediatric Liver Transplantation Neema Kaseje 1 Samuel Lüthold 2 Gilles Mentha 3 Christian Toso 3 Dominique Belli 2 Valérie McLin 2 Barbara
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29755 holds various files of this Leiden University dissertation. Author: Moes, Dirk Jan Alie Roelof Title: Optimizing immunosuppression with mtor inhibitors
More informationTHE PHARMACOKINETICS OF SINGLE DOSE VS STEADY-STATE DOSES OF PROPRANOLOL IN CIRRHOTIC MALAY PATIENTS
Malaysian Journal of Medical Sciences, Vol. 9, No. 1, January 2002 (16-20) ORIGINAL ARTICLE THE PHARMACOKINETICS OF SINGLE DOSE VS STEADY-STATE DOSES OF PROPRANOLOL IN CIRRHOTIC MALAY PATIENTS Zain-Hamid,
More informationDRUG LEVEL MONITORING AND ADJUSTMENT Silvio Sandrini, Brescia, Italy Chairs: Ryszard Grenda, Warsaw, Poland Julio Pascual, Barcelona, Spain
DRUG LEVEL MONITORING AND ADJUSTMENT Silvio Sandrini, Brescia, Italy Chairs: Ryszard Grenda, Warsaw, Poland Julio Pascual, Barcelona, Spain Prof. Silvio Sandrini Division and Chair of Nephrology University
More informationDrug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila
Drug Dosing in Renal Insufficiency Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila Declaration of Conflict of Interest For today s lecture on Drug Dosing in Renal
More informationNIH Public Access Author Manuscript Res Commun Chem Pathol Pharmacol. Author manuscript; available in PMC 2010 October 18.
NIH Public Access Author Manuscript Published in final edited form as: Res Commun Chem Pathol Pharmacol. 1986 July ; 53(1): 137 140. EFFECT OF BILE ON CYCLOSPORINE ABSORPTION IN DOGS Raman Venkataramanan
More informationEmerging Drug List EVEROLIMUS
Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine
More informationLothar Bernd Zimmerhackl
What works in current paediatric practice of off-label dose adjustment of adult doses? Lothar Bernd Zimmerhackl Medical University Innsbruck Austria AGAH Workshop: Pediatric Investigation Plan. Bonn 13-14.1.
More informationROUTINE LAB STUDIES. Routine Clinic Lab Studies
ROUTINE LAB STUDIES Routine Clinic Lab Studies With all lab studies, a tacrolimus or cyclosporine level will be obtained. These drug levels are routinely assessed to ensure that there is enough or not
More informationPharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients
clinical investigation http://www.kidney-international.org & International Society of Nephrology Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients
More informationThis PDF is available for free download from a site hosted by Medknow Publications
Educational Forum Therapeutic drug monitoring of immunosuppressants: An overview Sukhpreet, P. Tiwari Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER),
More informationDevelopment of population PK model with enterohepatic circulation for mycophenolic acid in patients with. childhood-onset systemic lupus erythematosus
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2011.04140.x Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic
More informationIncreased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation
Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation Gary W Barone 1, Beverley L Ketel 1, Sameh R Abul-Ezz 2, Meredith L Lightfoot 1 1 Department of Surgery
More informationControversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital
Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids
More informationBasic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics
Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Learning Outcomes Define biopharmaceutics Describe 4 processes of pharmacokinetics Describe factors that affect medication absorption Describe
More informationSang Ling Wu, MD, Wei Li, MD, PhD, Alice Wells, MT(ASCP), and Amitava Dasgupta, PhD
Clinical Chemistry / DIGOXIN-LIKE AND DIGITOXIN-LIKE IMMUNOREACTIVE SUBSTANCES IN ELDERLY PEOPLE Digoxin-Like and Digitoxin-Like Immunoreactive Substances in Elderly People Impact on Therapeutic Drug Monitoring
More informationSponsor / Company: Sanofi Drug substance: SAR236553/REGN727 (alirocumab)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance:
More informationTo cite this version: HAL Id: inserm
Performance of the new mycophenolate assay based on IMPDH enzymatic activity for pharmacokinetic investigations and setup of Bayesian estimators in different populations of allograft recipients. Pierre
More informationC OBJECTIVES. Basic Pharmacokinetics LESSON. After completing Lesson 2, you should be able to:
LESSON 2 Basic Pharmacokinetics C OBJECTIVES After completing Lesson 2, you should be able to: 1. Define the concept of apparent volume of distribution and use an appropriate mathematical equation to calculate
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationCyclosporine A Withdrawal during Follow-Up After Pediatric Liver Transplantation
LIVER TRANSPLANTATION 12:240-246, 2006 ORIGINAL ARTICLE Cyclosporine A Withdrawal during Follow-Up After Pediatric Liver Transplantation Rene Scheenstra, 1 Maarten L.J. Torringa, 2 Herman J. Waalkens,
More informationThis study is currently recruiting participants.
A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation This study is currently recruiting
More informationPost-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies
Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Lorita M Rebellato, Ph.D., D (ABHI) Associate Professor Department of Pathology The Brody School of Medicine at ECU Scientific
More informationOriginal Article Estimation of optimal minimum dosage of mycophenolate mofetil in children with various glomerular diseases
Int J Clin Exp Med 2018;11(1):316-326 www.ijcem.com /ISSN:1940-5901/IJCEM0050850 Original Article Estimation of optimal minimum dosage of mycophenolate mofetil in children with various glomerular diseases
More informationBioequivalence Studies of Two Formulations of Famciclovir Tablets by HPLC Method
Asian Journal of Chemistry Vol. 19, No. 6 (2007), 4245-4250 Bioequivalence Studies of Two Formulations of Famciclovir Tablets by HPLC Method K.V. SUBRAHMANYAM*, P. MOHANRAJ, P. SANDHYARANI, V.S. SARAVANAN
More informationEvaluation of limited sampling strategies for tacrolimus
Eur J Clin Pharmacol (2007) 63:1039 1044 DOI 10.1007/s00228-007-0354-9 PHARMACOKINETICS AND DISPOSITION Evaluation of limited sampling strategies for tacrolimus Robert A. M. Op den Buijsch & Afke van de
More informationTacrolimus-Induced Neutropenia in Renal Transplant Recipients
CJASN epress. Published on January 21, 2011 as doi: 10.2215/CJN.07320810 Special Features Tacrolimus-Induced Neutropenia in Renal Transplant Recipients Anja De Rycke,* Daan Dierickx, and Dirk R. Kuypers*
More informationFixed- or Controlled-Dose Mycophenolate Mofetil with Standard- or Reduced-Dose Calcineurin Inhibitors: The Opticept Trial
American Journal of Transplantation 2009; 9: 1607 1619 Wiley Periodicals Inc. C 2009 The Authors Journal compilation C 2009 The American Society of Transplantation and the American Society of Transplant
More informationCyclosporine (CsA) dose adjustments based on. C 2 Monitoring of Cyclosporine in De Novo Liver Transplant Recipients: The Clinician s Perspective
REVIEW C 2 Monitoring of Cyclosporine in De Novo Liver Transplant Recipients: The Clinician s Perspective Federico Villamil 1 and Stephen Pollard 2 Adjusting cyclosporine (CsA) dose based on blood concentration
More informationtients with insufficient TOR inhibitor therapy that are at risk for rejection.
Kidney International, Vol. 68 (05), pp. 2593 2598 Biochemical monitoring of mtor inhibitor based immunosuppression following kidney transplantation: A novel approach for tailored immunosuppressive therapy
More informationROLE OF MRP2 IN THE HEPATIC DISPOSITION OF MYCOPHENOLIC ACID AND ITS GLUCURONIDE METABOLITES: EFFECT OF CYCLOSPORINE
0090-9556/06/3402-261 266$20.00 DRUG METABOLISM AND DISPOSITION Vol. 34, No. 2 Copyright 2006 by The American Society for Pharmacology and Experimental Therapeutics 6122/3078184 DMD 34:261 266, 2006 Printed
More informationConsidering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol
Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Patient details Name DOB ESRD Other history Mr. B.I.B. 12 January 1975 (34yo) Membranous GN
More informationOrgan rejection is one of the serious
Original Article Outcomes of Late Corticosteroid Withdrawal after Renal Transplantation in Patients Exposed to Tacrolimus and/or Mycophenolate Mofetil: Meta-Analysis of Randomized Controlled Trials A.
More informationHow to improve long term outcome after liver transplantation?
How to improve long term outcome after liver transplantation? François Durand Hepatology & Liver Intensive Care University Paris Diderot INSERM U1149 Hôpital Beaujon, Clichy PHC 2018 www.aphc.info Long
More informationS. George* and R.A. Braithwaite Regional Laboratory for Toxicology, City Hospital NHS Trust, Dudley Road, Birmingham, England, B 18 7QH.
A Pilot Study to Determine the Usefulness of the Urinary Excretion of Methadone and its Primary Metabolite (EDDP) as Potential Markers of Compliance in Methadone Detoxification Programs S. George* and
More informationRoutine Clinic Lab Studies
Routine Lab Studies Routine Clinic Lab Studies With all lab studies, a Tacrolimus level will be obtained. These drug levels are routinely assessed to ensure that there is enough or not too much anti-rejection
More informationSteroid Minimization: Great Idea or Silly Move?
Steroid Minimization: Great Idea or Silly Move? Disclosures I have financial relationship(s) within the last 12 months relevant to my presentation with: Astellas Grants ** Bristol Myers Squibb Grants,
More informationTransplant Hepatology
Transplant Hepatology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified
More informationAMIODARONE and DESETHYLAMIODARONE IN PLASMA BY UV FAST CODE Z33610
AMIODARONE and DESETHYLAMIODARONE IN PLASMA BY UV FAST CODE Z33610 INTRODUCTION Amiodarone is an antiarrhythmic agent used for various types of tachyarrhythmias, both ventricular and supraventricular arrhythmias.
More informationDate: 23 June Context and policy issues:
Title: Basiliximab for Immunosuppression During a Calcineurin Inhibitor Holiday in Renal Transplant Patients with Acute Renal Dysfunction: Guidelines for Use and a Clinical and Cost-Effectiveness Review
More informationLiterature Review: Transplantation July 2010-June 2011
Literature Review: Transplantation July 2010-June 2011 James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Kidney Transplant Top 10 List: July Kidney
More informationPediatric Pharmacotherapy
Pediatric Pharmacotherapy A Monthly Review for Health Care Professionals of the Children's Medical Center Volume 4 Number 8, August 1998 Mycophenolate mofetil: Use in pediatrics Beth Ann Fullmer, R.Ph.,
More informationORIGINAL ARTICLE. PATIENTS AND METHODS Liver transplantation
LIVER TRANSPLANTATION 12:1342-1346, 2006 ORIGINAL ARTICLE Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Liver Transplant Patients Presenting Gastrointestinal Disorders:
More informationGeneral Principles of Pharmacology and Toxicology
General Principles of Pharmacology and Toxicology Parisa Gazerani, Pharm D, PhD Assistant Professor Center for Sensory-Motor Interaction (SMI) Department of Health Science and Technology Aalborg University
More informationFlecainide pharmacokinetics in healthy volunteers: the influence of urinary ph
Br. J. clin. Pharmac. (1985), 20, 333-338 Flecainide pharmacokinetics in healthy volunteers: the influence of urinary ph A. JOHNSTON, S. WARRNGTON' & P. TURNER Department of Clinical Pharmacology, St Bartholomew's
More informationDepartment of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai , China
Biomedicine and Biotechnology Volume 2012, Article ID 386230, 4 pages doi:10.1155/2012/386230 Research Article The Difference in Pharmacokinetics and Pharmacodynamics between Extended-Release Fluvastatin
More informationRenalase: A Novel Inflamatory Marker Post Living Donor Liver Transplantation
Med. J. Cairo Univ., Vol. 86, No. 5, September: 2741-2745, 2018 www.medicaljournalofcairouniversity.net Renalase: A Novel Inflamatory Marker Post Living Donor Liver Transplantation AHMED M. ABDUL GHANI,
More informationEFFECT OF MODERATE HEPATIC INSUFFICIENCY ON THE PHARMACOKINETICS OF SITAGLIPTIN
EFFECT OF MODERATE HEPATIC INSUFFICIENCY ON THE PHARMACOKINETICS OF SITAGLIPTIN Elizabeth M Migoya 1, Catherine H Stevens 1, Arthur J Bergman 1, Wen-lin Luo 1, Kenneth C Lasseter 2, Stacy C Dilzer 2, Michael
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More informationOutline. How should we do TDM? Does the evidence support TDM outcomes
Overcoming Barriers to TDM: Information and the TDM Renaissance How to integrate PK intelligence with routine clinical data Alexander A. Vinks, PharmD, PhD, FCP Professor, Director Pediatric Pharmacology
More informationProton pump inhibitors do not increase the risk of acute rejection
ORIGINAL ARTICLE Proton pump inhibitors do not increase the risk of acute rejection G.A.J. van Boekel*, C.H.H. Kerkhofs, F. van de Logt, L.B. Hilbrands Department of Nephrology, Radboud University Medical
More information